Entries by sylviedetry

OSE Immunotherapeutics to Present New Data on OSE-172 at American Association for Cancer Research Annual Meeting 2018, Chicago, April 14-18

OSE-172, SIRPa Antagonist, Prevents Metastasis Spread in Aggressive Cancer Models; Decreases Tumor Growth and Suppressive Function of Tumor Myeloid Cells, MDSC and M2 Macrophages, in Various Cancers Models; Potentiates Dendritic Cell Tumor Antigen Cross-Presentation Increasing T-Cell Specific …     Activation.